FGFR3 and urinary bladder neoplasm: The identification of the appropriate subset(s) of UBC patients who will benefit most from FGFR-directed therapy is a significant challenge as not all patients with FGFR3 mutated bladder tumors respond to FGFR inhibition, and there are also responders without FGFR3 alterations [166].